Healthcare Professionals: ORIGIN Overview
ORIGIN (Outcome Reduction with Initial Glargine Intervention) a long-term, international clinical trial assessing the effect of more than six years of therapy with basal insulin (supplied as insulin glargine) on cardiovascular and other health outcomes in high risk people with dysglycemia (i.e. either pre-diabetes or type 2 diabetes). The trial also examined the effect of omega-3 fatty acid supplements (provided as omega 3 ethyl ester 90 or Omacor) on preventing cardiovascular events in this population.
- 12,537 participants from 573 sites in 40 countries around the world
- 8,600 participants provided full blood samples; 5,500 genetic samples; 11,800 urine samples
- 2.2 million case report forms completed
- 21 approved sub studies